诺诚健华奥布替尼获国家药监局批准开展治疗多发性硬化临床II期研究

美通社
14 Apr 2021

原标题:诺诚健华奥布替尼获国家药监局批准开展治疗多发性硬化临床II期研究 来源:美通社北京2021年4月14日 -- 诺诚健华今天宣布,公司旗下布鲁顿酪氨酸激酶(BTK)抑制剂奥布替尼用于治疗多发性硬化(MS)已经通过中国国家药品监督管理局(NMPA)的临床研究用新药(IND)审评,获批在中国开展临床II期研究。这是一项评估奥布替尼用于多发性硬化患者的国际多中心临床II期研究,将评估其有效性、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10